Sign In
Buy SAGE
$8.68
+0 (+0%)
At Close: Oct 30, 2025
Sage Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Highlights Pipeline and Business Progress
06:30am, Wednesday, 24'th Feb 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Today, Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform th
Sage Therapeutics, Inc. (SAGE) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
01:40pm, Wednesday, 17'th Feb 2021
Sage Therapeutics, Inc. (SAGE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sage Therapeutics to Present at Upcoming Investor Conferences
05:00pm, Thursday, 11'th Feb 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives
Sage Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on Wednesday, February 24, 2021
06:30am, Wednesday, 10'th Feb 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives
American BriVision: Deep Dive Into Market Potential
03:38pm, Thursday, 14'th Jan 2021
American BriVision: Deep Dive Into Market Potential
Sage Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021
06:30am, Wednesday, 23'rd Dec 2020
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives
Sage Therapeutics Announces the Appointment of Barry Greene as CEO
06:30am, Wednesday, 16'th Dec 2020
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of pe
3 Stocks That Are Giving Their Investors Coal in Their Stockings
07:20am, Saturday, 12'th Dec 2020
Naughty or nice, shareholders aren't getting anything on their wish lists from these stocks this year.
Sage Therapeutics' Deal With Biogen Should Revive It
01:23am, Friday, 11'th Dec 2020
Biogen recently announced a $1.5 billion collaboration agreement with Sage Therapeutics. Despite an earlier failed trial, Zuranolone is a promising therapy for depression.
Sage Therapeutics to Present at BMO 2020 Growth & ESG Conference
04:30pm, Thursday, 03'rd Dec 2020
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives
Sage Stock Slips Amid Biogen Deal Critique
11:57am, Tuesday, 01'st Dec 2020
The shares of Sage Therapeutics Inc (NASDAQ:SAGE) are down 1.8% at $72.78 at last check, after Raymond James downgraded the stock to "Market Perform" from "Outperform," following its recent $1.5 billi
Sage Therapeutics to receive $1.525 billion in cash in deal with Biogen to jointly develop depression, tremor therapies
07:43am, Friday, 27'th Nov 2020
Biogen Inc. and Sage Therapeutics Inc. said Monday they have agreed to jointly develop therapies to treat depression and movement disorders in a deal in which Biogen will give Sage $1.525 billion in c
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics, Inc. (Nasdaq: SAGE) announced that they have executed a global collaboration and license agreement
Sage Therapeutics' (SAGE) Management on Q3 2020 Results - Earnings Call Transcript
03:35pm, Thursday, 05'th Nov 2020
Sage Therapeutics' (SAGE) Management on Q3 2020 Results - Earnings Call Transcript
Sage Therapeutics: Q3 Earnings Insights
08:56am, Thursday, 05'th Nov 2020
Shares of Sage Therapeutics (NASDAQ: SAGE) were unchanged after the company reported Q3 results. Quarterly Results Earnings per share increased 41.67% year over year to ($2.03), which beat the estima
